4.7 Article

Local Fractional Anisotropy Is Reduced in Areas with Tumor Recurrence in Glioblastoma

Journal

RADIOLOGY
Volume 283, Issue 2, Pages 499-507

Publisher

RADIOLOGICAL SOC NORTH AMERICA (RSNA)
DOI: 10.1148/radiol.2016152832

Keywords

-

Funding

  1. Brainlab AG
  2. Medtronic
  3. Integra
  4. Brainlab
  5. Signus
  6. Ulrich
  7. Biogen Idec
  8. Quintiles
  9. MSD Sharp Dome
  10. Boehringer Ingelheim
  11. Inventive Health Clinical UK
  12. Advance Cor
  13. Brainsgate
  14. Pfizer
  15. Bayer-Schering
  16. Novartis
  17. Roche
  18. Servier
  19. Penumbra
  20. WCT GmbH
  21. Syngis
  22. SSS Internartional Clinical Research
  23. PPD Germany GmbH
  24. Worldwide Clinical Trials
  25. Phenox
  26. Covidien
  27. Actelion
  28. Medivation
  29. Harrison Clinical Research
  30. Concentric
  31. Pharmtrace
  32. Reverse Medical
  33. Premier Research Germany
  34. Surpass Medical
  35. GlaxoSmithKline
  36. German Research Foundation
  37. European Research Council

Ask authors/readers for more resources

Purpose: To analyze if fractional anisotropy (FA) in nonenhancing peritumoral regions (NEPTRs) at baseline is associated with later tumor recurrence in glioblastoma. Materials and Methods: Ethical approval was obtained for this retrospective, HIPAA-compliant study. FA was measured in 70 patients with glioblastoma in five regions of interest (ROIs) per patient in the NEPTR at preoperative magnetic resonance (MR) imaging with (166 regions) or without (184 regions) local contrast-enhancing tumor recurrence at follow- up MR imaging (median, 7.3 months; range, 0.9-46.6 months). ROIs were classified according to their location (white matter, cortex, fiber tracts, basal ganglia). Ratio of FA in the ROI of the NEPTR to that in the contralateral side (FA contra) and to that in the internal capsule (FA int) was calculated. A generalized linear mixed model was performed. Ten-fold cross-validation was used for the receiver operating characteristics (ROC) analysis. Results: FA contra and FA int were significantly lower in regions with later tumor recurrence than in regions without (median FA contra : 0.29 [interquartile range {IR}, 0.22-0.36] vs 0.46 [IR, 0.38-0.57]; median FA int : 0.20 [IR, 0.16-0.24] vs 0.29 [IR, 0.22-0.36], respectively). ROC analysis revealed an area under the ROC curve of 0.893 for FA contra and of 0.815 for FA int, resulting in respective sensitivity and specificity of 85.5% and 84.2% for FA contra and 86.7% and 66.8% for FA int. Conclusion: Local tumor recurrence in the NEPTR may be predicted by FA metrics at baseline in patients with glioblastoma. This might be important for surgery or radiation planning.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available